Trials / Sponsors / iCell Gene Therapeutics
iCell Gene Therapeutics
Industry · 14 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | BCMA-CD19 cCAR T for the Treatment of Refractory Lupus Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 / Phase 2 | 2026-01-01 |
| Recruiting | BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases Refractory Immune Cytopenia | Phase 1 | 2024-08-31 |
| Unknown | CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma | Phase 1 | 2022-07-01 |
| Unknown | Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies | Phase 1 | 2022-07-01 |
| Unknown | BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) | Phase 1 | 2022-04-01 |
| Unknown | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | 2020-12-01 |
| Unknown | Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma | Phase 1 | 2020-12-01 |
| Unknown | CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies T Cell Lymphoma in Relapse, Refractory T-Cell Lymphoma | Phase 1 | 2019-07-11 |
| Recruiting | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma | Phase 1 | 2019-07-01 |
| Unknown | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma Multiple Myeloma | EARLY_Phase 1 | 2018-08-31 |
| Unknown | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies B Cell Lymphoma, B Cell Leukemia | EARLY_Phase 1 | 2018-08-01 |
| Unknown | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes | EARLY_Phase 1 | 2018-03-01 |
| Unknown | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes | EARLY_Phase 1 | 2018-03-01 |
| Unknown | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies B Cell Lymphoma, B Cell Leukemia | EARLY_Phase 1 | 2018-02-01 |